Thatte, J., Moisés da Silva, A., Börcsök, J., Gudjónsson, T., Benada, J., Li, X., … Sørensen, C. S. (2025). The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. Journal of Clinical Investigation, 135(11). https://doi.org/10.1172/jci188165

Thatte, Jayashree, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, et al. “The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.” Journal of Clinical Investigation 135, no. 11 (June 2, 2025). https://doi.org/10.1172/jci188165.

Thatte J, Moisés da Silva A, Börcsök J, Gudjónsson T, Benada J, Li X, et al. The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. Journal of Clinical Investigation. 2025 Jun 2;135(11).

Thatte, Jayashree, et al. “The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.” Journal of Clinical Investigation, vol. 135, no. 11, American Society for Clinical Investigation, June 2025. Crossref, doi:10.1172/jci188165.

Thatte J, Moisés da Silva A, Börcsök J, Gudjónsson T, Benada J, Li X, Bose M, van der Gulden H, Song J-Y, Menezes R, Martín-Doncel E, Toledo L, Petrosius V, Brakebusch C, Jonkers J, Nielsen FC, Rossing M, Sørensen CS. The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression. Journal of Clinical Investigation. American Society for Clinical Investigation; 2025 Jun 2;135(11).